Join Growin Stock Community!

旭富4119.TW Overview

TW StockBiotech. & Medical
(No presentation for 4119)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

旭富（4119）Overall Performance

旭富（4119）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

旭富（4119） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

旭富（4119）Key Information

旭富（4119）Profile

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and specialty chemicals. Its active pharmaceutical ingredients include Articaine HCl, Atomoxetine HCl, Bisoprolol Fumarate, Brinzolamide, Divalproex Sodium, Duloxetine HCl, Hydroxychloroquine sulfate, Loxoprofen Sodium, Methylphenidate HCl, Pentobarbital Sodium, Probucol, Propafenone HCl, Sodium Valproate, Thiopental, Valproic Acid, Adenine, Cannabidiol, and Dexmethylphenidate HCl. The company's intermediate products comprise Azetidin-3-ol hydrogenchloride, Diethyl Isobutyl Malonate, Diethyl dipropylmalonate, Diethyl ethyl(1-methylbutyl)malonate, Pyrogallolaldehyde, Benzhydrylamine, 1-Benzhydrylazetidin-3-ol, 1-(2-Hydroxyphenyl)-3-phenylpropan-1-one, N-Methyl-4-piperidinol, Ritalinic acid, d-Ritalinic acid HCl, (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol HCl, and (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol. Its intermediate products also consists of (S)-3-(methylmino)-1-(2-thi-enyl)propan-1-ol, (R)-3-(Methylamino)-1-phenylpropanol, (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol, Menthadienol, 5-pentylbenzene-1,3-diol Olivetol, Methyl 2,4-dihydroxy-6-pentylbenzoate, and Ethyl 2,4-dihydroxy-6-pentylbenzoate Ethyl Olivetolate. The company also provides custom manufacturing services. It sells its products in Italy, China, the United States, Germany, Taiwan, Switzerland, Spain, Japan, Netherlands, and internationally. The company was incorporated in 1987 and is based in Taoyuan City, Taiwan.

旭富（4119）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.97
PE Ratio (TTM)
53.67
Forward PE
27.55
PS Ratio (TTM)
4.45
PB Ratio
1.15
Price-to-FCF
13.17
METRIC
VALUE
vs. INDUSTRY
Gross Margin
24.91%
Net Margin
8.30%
Revenue Growth (YoY)
-1.64%
Profit Growth (YoY)
-9.64%
3-Year Revenue Growth
-5.57%
3-Year Profit Growth
-9.76%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.97
PE Ratio (TTM)
53.67
Forward PE
27.55
PS Ratio (TTM)
4.45
PB Ratio
1.15
Price-to-FCF
13.17
Gross Margin
24.91%
Net Margin
8.30%
Revenue Growth (YoY)
-1.64%
Profit Growth (YoY)
-9.64%
3-Year Revenue Growth
-5.57%
3-Year Profit Growth
-9.76%
default symbol

4119

旭富

51.80D

-1.74%

(-0.02)

  • When is 4119's latest earnings report released?

    The most recent financial report for 旭富 (4119) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4119's short-term business performance and financial health. For the latest updates on 4119's earnings releases, visit this page regularly.

  • Where does 4119 fall in the P/E River chart?

    According to historical valuation range analysis, 旭富 (4119)'s current price-to-earnings (P/E) ratio is 64.35, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 4119?

    According to the latest financial report, 旭富 (4119) reported an Operating Profit of 18.73M with an Operating Margin of 7.3% this period, representing a decline of 63.21% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4119's revenue growth?

    In the latest financial report, 旭富 (4119) announced revenue of 256.44M, with a Year-Over-Year growth rate of -38.84%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4119 have?

    At the end of the period, 旭富 (4119) held Total Cash and Cash Equivalents of 63.57M, accounting for 0.01 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4119 go with three margins increasing?

    In the latest report, 旭富 (4119) achieved the “three margins increasing” benchmark, with a gross margin of 26.66%%, operating margin of 7.3%%, and net margin of 5.46%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4119's profit trajectory and future growth potential.

  • Is 4119's EPS continuing to grow?

    According to the past four quarterly reports, 旭富 (4119)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.12. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4119?

    旭富 (4119)'s Free Cash Flow (FCF) for the period is 85.81M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 64.44% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.